WithdrawnPhase 3NCT00406172

Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

Studying Cystoid macular dystrophy

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Asociación para Evitar la Ceguera en México
Principal Investigator: Victoria Cubas-Lorenzo, MD
APEC México
Intervention: Bevacizumab(drug)
Eligibility: All sexes
Timeline: 2006 – 2006

Study locations (1)

APEC, México D.F., Mexico

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00406172 on ClinicalTrials.gov

Other trials for Cystoid macular dystrophy

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1, PHASE2NCT04225611
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
Massachusetts Eye and Ear Infirmary

See all trials for Cystoid macular dystrophy →

← Back to all trials